Journal of Breast Cancer最新文献

{"title":"Residual Risk of Ipsilateral Tumor Recurrence in Patients Who Achieved Clear Lumpectomy Margins After Repeated Resection","authors":"Jong-Ho Cheun, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Hyeong-Gon Moon","doi":"10.4048/jbc.2023.26.e46","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e46","url":null,"abstract":"PURPOSE\u0000Patients with breast cancer with positive lumpectomy margins have a two-fold increased risk of ipsilateral breast tumor recurrence (IBTR). This can be the result of either technically incomplete resection or the biological characteristics of the tumor that lead to a positive margin. We hypothesized that if achieving negative margins by re-excision nullifies the IBTR risk, then the increased risk is mainly attributed to the technical incompleteness of the initial surgeries. Thus, we investigated IBTR rates in patients with breast cancer who achieved clear margins after re-excision.\u0000\u0000\u0000METHODS\u0000We retrospectively reviewed patients who underwent breast lumpectomy for invasive breast cancer between 2004 and 2018 at a single institution, and investigated IBTR events.\u0000\u0000\u0000RESULTS\u0000Among 5,598 patients, 793 achieved clear margins after re-excision of their initial positive margins. During the median follow-up period of 76.4 months, 121 (2.2%) patients experienced IBTR. Patients who underwent re-excision to achieve negative margin experienced significantly higher IBTR rates compared to those achieving clear margin at first lumpectomy (10-year IBTR rate: 5.3% vs. 2.6% [25 vs. 84 events]; unadjusted p = 0.031, hazard ratio, 1.61, 95% confidence interval [CI], 1.04-2.48; adjusted p = 0.030, hazard ratio, 1.69, 95% CI, 1.05-2.72). This difference was more evident in patients aged < 50 years and those with delayed IBTR. Additionally, no statistically significant differences were observed in the spatial distribution of IBTR locations.\u0000\u0000\u0000CONCLUSION\u0000Patients who underwent re-excision for initial positive margins had an increased risk of IBTR, even after achieving a final negative margin, compared to patients with negative margins initially. This increased risk of IBTR is mostly observed in young patients and delayed cases.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"122 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134882302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of and Influencing Factors for Arm Lymphedema After Salvage Treatment for an Isolated Locoregional Recurrence of Breast Cancer","authors":"Nalee Kim, Haeyoung Kim, Ji Hye Hwang, Jeong Eon Lee, Won Park, Won Kyung Cho, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Tae-Gyu Kim","doi":"10.4048/jbc.2023.26.e43","DOIUrl":"https://doi.org/10.4048/jbc.2023.26.e43","url":null,"abstract":"PURPOSE\u0000Data on subsequent arm lymphedema (SAL) after salvage treatment for locoregional recurrence (LRR) of breast cancer are limited. We conducted a study to evaluate the risk of SAL in patients with LRR.\u0000\u0000\u0000METHODS\u0000We reviewed the data of patients with breast cancer who had LRR and were initially diagnosed between January 2003 and December 2017. Among the 214 patients who received curative salvage treatment, most had local (n = 125, 57.9%), followed by regional (n = 73, 34.1%), and locoregional (n = 16, 7.9%) recurrences. A competing risk analysis considering the factors of death and a second LRR were performed to exclude potential malignant lymphedema. We used the Fine-Gray subdistribution hazards model to estimate the hazard ratio (HR) for comparing the risk of SAL.\u0000\u0000\u0000RESULTS\u0000With a median follow-up duration of 41.4 months (interquartile range, 25.6-65.1), 51 patients (23.8%) experienced SAL with a median interval of 9.9 months after treatment. The two-year cumulative incidence of SAL was 12.7%. Among the 18 patients with initial lymphedema, nine (50.0%) developed SAL. Multivariate analysis revealed that a history of lymphedema (HR, 4.61; p < 0.001) and taxane-based salvage chemotherapy (HR, 2.38; p = 0.009) were significantly associated with SAL development.\u0000\u0000\u0000CONCLUSION\u0000Salvage treatment for LRR-induced SAL was performed in 24% of the patients. A history of initial lymphedema and salvage taxane-based chemotherapy increases the risk of developing SAL. Therefore, close surveillance for the incidence of SAL is required in patients opting for salvage treatment for LRR.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"146 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135156701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Apocrine Lesions of the Breast: Multimodality Imaging Findings and Biologic Features.","authors":"Hyo-Jae Lee,&nbsp;Seung Wan Kang,&nbsp;Jong Eun Lee,&nbsp;Won Gi Jeong,&nbsp;Ji Shin Lee,&nbsp;Min Ho Park,&nbsp;Hyo Soon Lim","doi":"10.4048/jbc.2022.25.e46","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e46","url":null,"abstract":"<p><p>The apocrine morphology of the breast is observed in a broad pathological spectrum, ranging from benign cysts to invasive carcinomas. However, the number of clinical research investigating malignant apocrine lesions is limited. This study retrospectively reviewed the data of patients with malignant apocrine lesions admitted in a tertiary center between January 2004 and December 2021, based on the radiology-pathology correlation and the recent advances in their status to enhance the therapeutic implications of androgen receptor (AR). Among the 37 patients with lesions, 27 (73.0%) had triple-negative subtypes with predominant AR expression. The radiological features of malignant apocrine lesions did not differ from those of typical invasive ductal carcinoma or ductal carcinoma in situ. This study demonstrated that knowledge on the imaging features of malignant apocrine lesions and their histological basis could enhance the adoption of new targeted therapies in patients with this particular type of breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"513-521"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/94/jbc-25-513.PMC9807319.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceramide Synthase 6 Mediates Triple-Negative Breast Cancer Response to Chemotherapy Through RhoA- and EGFR-Mediated Signaling Pathways.","authors":"Hui Chen,&nbsp;Bin He,&nbsp;Feng Ke","doi":"10.4048/jbc.2022.25.e47","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e47","url":null,"abstract":"<p><strong>Purpose: </strong>Limited treatment options and lack of treatment sensitivity biomarkers make the clinical management of triple-negative breast cancer (TNBC) challenging. Ceramide synthase 6 (CERS6) generates ceramides, which are key intermediates in sphingolipid biosynthesis and play important roles in cancer progression and resistance.</p><p><strong>Methods: </strong>CERS6 was analyzed to determine its potential as a treatment sensitivity biomarker. CERS6 levels were determined in patients with breast cancer, and the roles and downstream signaling of CERS6 were analyzed using cellular and biochemical assays.</p><p><strong>Results: </strong>Analysis of CERS6 expression in 195 patients with TNBC and their clinical response to chemotherapy revealed that individuals with CERS6 overexpression experienced significantly inferior responses to chemotherapy than those without CERS6 overexpression. Functional analysis demonstrated that although CERS6 overexpression did not affect TNBC cell growth and migration, it conferred chemoresistance. CERS6 inhibition significantly reduced growth, migration, and survival by suppressing the RhoA- and EGFR-mediated signaling pathways. Compared to control cells, CERS6-depleted cells were consistently less viable at different concentrations of chemotherapeutic agents.</p><p><strong>Conclusion: </strong>Our study is the first to demonstrate that CERS6 may serve as a treatment sensitivity biomarker in patients with TNBC in response to chemotherapy. In addition, our findings suggested that CERS6 may be a therapeutic target for TNBC treatment.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"500-512"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/ee/jbc-25-500.PMC9807320.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10863230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay.","authors":"Jun-Hee Lee,&nbsp;Jai Min Ryu,&nbsp;Jee Hyun Ahn,&nbsp;Soo Youn Cho,&nbsp;Se Kyung Lee,&nbsp;Jonghan Yu,&nbsp;Byung Joo Chae,&nbsp;Seok Jin Nam,&nbsp;Jinil Han,&nbsp;Jeong Eon Lee,&nbsp;Seok Won Kim","doi":"10.4048/jbc.2022.25.e49","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e49","url":null,"abstract":"<p><strong>Purpose: </strong>The GenesWell™ breast cancer test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with hormone receptor-positive (HR+) and human epidermal growth factor-2 negative (HER2-) early breast cancer (BC). The ability of this assay to predict the response to neoadjuvant chemotherapy (NACT) has not been established to date.</p><p><strong>Methods: </strong>Biopsy specimens from HR+/HER2- BC patients with axillary lymph node (LN) metastasis who underwent NACT were analyzed using the BCT score. The modified BCT score was developed and patients classified into high-and low-response groups. A total of 88 patients were available for the BCT score among the 108 eligible patients. The median follow-up duration was 35.9 (7.8-128.5) months.</p><p><strong>Results: </strong>Among them, 61 (65.1%) had cN1 and 53 (60.2%) had cT1 or cT2 disease. The BCT score was low in 25 (28.4%) patients and high in 63 (71.6%). Among the 50 patients with pathologic complete response or partial response, 41 (82.0%) were in the high BCT score group and 9 (18.0%) were in the low BCT score group. Among the 38 patients with stable or progressive disease, 22 (57.9%) were in the high BCT score group and 16 (42.1%) were in the low BCT score group (<i>p</i> = 0.025). Ki-67 before NACT was a significant factor for predicting tumor response (<i>p</i> = 0.006; 3.81 [1.50-10.16]). The BCT score showed a significant response to NACT (<i>p</i> = 0.016; 4.18 [1.34-14.28]). Distant metastasis-free survival was significantly different between the high- and low-response groups (<i>p</i> = 0.004).</p><p><strong>Conclusion: </strong>We demonstrated that the BCT score predicts NACT responsiveness in HR+/HER2- BC with LN metastasis and might help determine whether NACT should be performed. Further studies are required to validate these results.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"473-484"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/c9/jbc-25-473.PMC9807325.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10863226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy After Breast Cancer - Prognostic Safety and Pregnancy Outcomes According to Oestrogen Receptor Status: A Systematic Review.","authors":"Katie Nolan,&nbsp;Michael R Boland,&nbsp;Arnold D K Hill","doi":"10.4048/jbc.2022.25.e45","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e45","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the primary cause of cancer-related death in women. Women diagnosed with estrogen receptor (ER)-positive breast cancer have prolonged treatment durations. Owing to the paucity of research and lack of consensus regarding conception planning and pregnancy for patients with ER-positive breast cancer, we aimed to assess pregnancy and survival outcomes in women with ER-positive breast cancer during and after treatment.</p><p><strong>Methods: </strong>We conducted a systematic review of the available studies on pregnancy after ER-positive breast cancer. The assessed outcomes included overall survival (OS), disease-free survival (DFS), hormonal therapy duration, and pregnancy outcomes.</p><p><strong>Results: </strong>Ultimately, 2,669 patients from five studies were included in this study. When all breast cancer receptor subtypes were included in the analysis, pregnancy after breast cancer was associated with a time-dependent protective effect on both DFS and OS. This protective effect was not evident when examining ER-positive patients with subsequent pregnancies, and no significant differences in DFS were observed. ER-positive patients who became pregnant received significantly lower rates of hormonal therapy. Hormonal treatment at the time of pregnancy was correlated with increased rates of termination owing to concerns about teratogenic effects.</p><p><strong>Conclusions: </strong>Pregnancy after breast cancer did not significantly affect DFS in ER-positive patients over a follow-up period of 5-10 years from diagnosis, although did significantly affect hormonal treatment duration in the reviewed studies. Further analysis and in-depth studies are required to assess the effects of altered hormonal treatment times, as well as patient management related to pregnancy planning after breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"443-453"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/59/jbc-25-443.PMC9807324.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10863224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic Mutations in Breast Cancer: The Tip of the Iceberg.","authors":"Jung Ho Park,&nbsp;Lee Su Kim","doi":"10.4048/jbc.2022.25.e52","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e52","url":null,"abstract":"Mutations of","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"523-524"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/1e/jbc-25-523.PMC9807321.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic Mutations of <i>TP53</i> and Prognostic Factors for Primary Operable Breast Cancer: Correspondence.","authors":"Pathum Sookaromdee,&nbsp;Viroj Wiwanitkit","doi":"10.4048/jbc.2022.25.e51","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e51","url":null,"abstract":"de Groot S, Baak-Pablo R, Kranenbarg EM, Seynaeve CM, van de Velde CJ, et al. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival. Sci Rep 2021;11:3249. PUBMED | CROSSREF","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"522"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/c9/jbc-25-522.PMC9807318.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis.","authors":"Zohreh Sanaat,&nbsp;Ozra Nouri,&nbsp;Monireh Khanzadeh,&nbsp;Hadi Mostafaei,&nbsp;Nafiseh Vahed,&nbsp;Neda Kabiri,&nbsp;Reza Ali Akbari Khoei,&nbsp;Hanieh Salehi-Pourmehr","doi":"10.4048/jbc.2022.25.e39","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e39","url":null,"abstract":"<p><strong>Purpose: </strong>Bisphosphonates (BPs) have a powerful effect on reducing bone resorption and improving the survival of patients with breast cancer. We aimed to investigate the impact of BP treatment on the prevention of recurrence, metastasis, and death of breast cancer survivors in the perimenopausal period.</p><p><strong>Methods: </strong>The search strategy aimed to identify both published and unpublished studies in PubMed, Web of Science, Scopus, Embase, ProQuest, and Google Scholar in March 2021. Two independent reviewers assessed quantitative papers selected for retrieval for methodological validity before being included in the review using standardized critical appraisal instruments from the Joanna Briggs Institute (JBI) Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI). Statistical meta-analysis was performed using Review Manager (RevMan) 5.4 statistical software when the data were homogenous. Meta-analysis was performed by calculating the effect size (hazard ratio; HR) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Twenty-one studies were eligible for this systematic review and meta-analysis. The overall The HRs for disease-free survival (DFS) and overall survival (OS) in women who received BPs were 0.89 (95% CI, 0.83-0.97; <i>p</i> = 0.005), and 0.75 (95% CI, 0.63-0.89; <i>p</i> = 0.001), respectively. The results showed that BPs had a significant effect on the prevention of locoregional (HR, 0.64; 95% CI, 0.42-0.97; <i>p</i> = 0.04), bone (95% CI, 0.74-0.95; <i>p</i> ≤ 0.001), and distant metastases (HR, 0.77; 95% CI, 0.62-0.94; <i>p</i> = 0.01). In the subgroup analysis based on study design, the only insignificant HR in the included randomized controlled trials (RCTs) was that of locoregional metastasis.</p><p><strong>Conclusion: </strong>Although BPs have a promising effect on DFS, OS, and bone metastasis of perimenopausal women survivors of breast cancer, more RCTs are needed to evaluate their effect on other survivors' outcomes.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"454-472"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dd/72/jbc-25-454.PMC9807326.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10512664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Increased Melanoma-Associated Antigen C2 Expression Affords Resistance to Apoptotic Deathin Suspension-Cultured Tumor Cells.","authors":"Doyeon Park,&nbsp;Sora Han,&nbsp;Hyunjeong Joo,&nbsp;Hye In Ka,&nbsp;Sujung Soh,&nbsp;Jiyoung Park,&nbsp;Young Yang","doi":"10.4048/jbc.2022.25.e48","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e48","url":null,"abstract":"<p><p>This corrects the article on p. 138 in vol. 24, PMID: 33818016.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 6","pages":"525"},"PeriodicalIF":2.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/1a/jbc-25-525.PMC9807323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10863225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}